MEA Biologics Market

MEA Biologics Market Size (2022 to 2027)

The Middle East & Africa biologics market size is expected to showcase a healthy growth rate during the forecast period.

MARKET DRIVERS:

There is an increase in High Throughput Screening (HTS) technology in the Middle East and Africa for various drug development processes. The technology is used to identify threads to discover an inhibitor of Middle East Respiratory Syndrome (MERS). This factor is attributed to fuel the growth rate of the biologics market in the MEA region. The increasing prevalence of diseases such as AIDS, Alzheimer's disease, and other drug-resistant infectious diseases has also led to the discovery new bioactive compounds that are likely to boost the market's growth rate.

Supply management for clinical trials is necessary to avoid overproduction, oversupply, and expiration of stocks. With the rising costs of drug discovery, supplies for clinical trials are gaining in importance. Hence a subsequent increase in the market for biologics.

MARKET RESTRAINTS:

Biologic drugs are very complex and must be controlled and maintained throughout the development and production process. This regulated environment and these quality control procedures involve significant capital investment in the initial phase of the process. In addition, biologics products are more sensitive to light and hot conditions and require an extremely promising environment that is not uniformly available globally.

In most emerging markets today, biologics products are scarce. Strict regulatory policies and high capital investments, coupled with limited patient access to biologics, mainly in developing countries, due to increased control and the cost of access to biologics, are likely to 'hamper the growth of the biologics market in the Middle East and Africa in the coming years.

Impact of COVID-19 on the MEA biologics market:

Since the increase in COVID-19 cases, the pharmaceutical industry has decreased its production capacity, leading to drug shortages. In addition, the diversion of resources from drug development to treatment for coronaviruses is likely to hamper the overall productivity of drug development for a short period of time.

Several pharmaceutical companies have decided to postpone ongoing clinical R&D due to disrupted supply chains and the threat of the virus. The Middle East is struggling to control the crisis due to the limited supply of health care due to the sanctions imposed by the United States on the country.

Such restrictions are likely to have a negative impact on research and development activities, directly limiting the growth of the biologics products market in the Middle East and Africa.

This research report on the MEA Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

• Microbial
• Mammalian
• Others

By Product:

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi, & Molecular Therapy
• Others

By Biologics Manufacturing:

• Outsourced
• In-house

By Disease Category:

• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the South African biologics market is estimated to be the most lucrative regional market in the MEA and is expected to register a promising growth rate during the forecast period. South Africa has started to focus on developing new drugs for progressive diseases. Due to the increase in acute and chronic diseases, the demand for small molecule therapies is increasing in the country. The Biosciences Unit of the Council for Scientific and Industrial Research (CSIR) is carrying out a large collaborative malaria research project with the help of biologics technology. Various public-private foundations fund the project, and more than 50 scientists contribute to the research project at various universities and research institutes in South Africa.

The UAE biologics market is another lucrative regional market and is predicted to showcase a healthy CAGR from 2022 to 2027. The country is dedicated to putting in place the necessary initiatives and infrastructure that could help develop the pharmaceutical value chain, which includes HTS, medical chemistry, and preclinical testing. This would increase drug biologics procedures, increase partnerships between companies and government organizations in the country to implement the process, and thus create wide opportunities for growth in the biologics market. These factors propel the demand of the market.

KEY MARKET PLAYERS:

A few prominent companies operating in the MEA biologics market profiled in this report are Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc.